Skip to main content
SpringerLink
Log in

Peripheral Neuropathy

  • Conference paper
Book cover Neurological Adverse Reactions to Anticancer Drugs

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

Abstract

Peripheral neuropathy is a common complication of antineoplastic chemotherapy. Several groups of drugs damage the peripheral nerves, giving rise to various clinical presentations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Holland JF, Scharlan C, Gaolani S et al: Vincristine treatment of advanced cancer: A cooperative study of 392 cases. Cancer Res 1973 (33):1258–1264

    PubMed  CAS  Google Scholar 

  2. Hildebrand J, Coers C: Etude clinique, histologique et électrophysiologique des neuropathies associées au traitement par la vincristine. Eur J Cancer 1965 (1):51–58

    Article  PubMed  CAS  Google Scholar 

  3. Sandler SG, Tobin W, Henderson ES: Vincristineinduced neuropathy. Neurology 1969 (19):367–374

    PubMed  CAS  Google Scholar 

  4. Nelimark RA, Peterson BA, Vosika GJ, Conroy JA: Vindesine for metastatic malignant melanoma. Am J Med 1983 (6):561–564

    CAS  Google Scholar 

  5. Jackson DV, Wells HB, Atkins JN, Zekan PJ et al: Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med 1988 (84):1016–1022

    Article  PubMed  CAS  Google Scholar 

  6. Favaro G, Di Gregorio F, Panozzo CH, Fiori MG: Ganglioside treatment of vincristine-induced neuropathy. An electrophysiologic study. Toxicology 1988 (49):325–329

    Article  PubMed  CAS  Google Scholar 

  7. Whitaker JA, Griffith IP: Recurrent laryngeal nerve paralysis in patients receiving vincristine and vinblastine. Br Med J 1977 (1):1251–1252

    Article  Google Scholar 

  8. Whitelaw DM, Cowan DH, Cassidy FR, Patterson TA: Clinical experience with vincristine. Cancer Chemother Rep 1963 (30):13–20

    PubMed  CAS  Google Scholar 

  9. Weiden PL, Wright SE: Vincristine neurotoxicity. N Engl J Med 1972 (286):1369–1370

    PubMed  CAS  Google Scholar 

  10. Michalak JC, Dibella NJ: Exacerbation of myotonia dystrophia by vincristine. N Engl Med 1976 (295):283

    CAS  Google Scholar 

  11. Hildebrand J, Kenis Y: Additive toxicity of vincristine and other drugs for the peripheral nervous system. Acta Neurol Belg 1971 (71):486–491

    PubMed  CAS  Google Scholar 

  12. De Vita VT, Serpick AA, Carbone PP: Combined chemotherapy in treatment of advanced Hodgkin’s disease. Ann Intern Med 1970 (73):881–895

    Google Scholar 

  13. Stewart DJ, Maroun JA, Lefebvre B, Heringer R: Neurotoxicity and efficacy of combined vinca alkaloids in breast cancer. Cancer Treat Rep 1986 (70):571–573

    PubMed  CAS  Google Scholar 

  14. Comis RL: Clinical trials of cyclophosphamide, etoposide and vincristine in the treatment of smallcell lung cancer. Sem Oncol 1986 (13):40–44

    CAS  Google Scholar 

  15. Watkins SM, Griffin JP: High incidence of vincristine-induced neuropathy in lymphomas. Br Med J 1978 (1):610–612

    Article  PubMed  CAS  Google Scholar 

  16. Aisner J, Weiss HD, Chang P, Wiernik PH: Orthostatic hypotension during combination chemotherapy with vincristine (NSC-67574). Cancer Chemother Rep 1974 (58):927–930

    PubMed  CAS  Google Scholar 

  17. Robertson GL, Bhoopalam N, Zelkowitz LJ: Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone. Arch Intern Med 1973 (132):717–720

    Article  PubMed  CAS  Google Scholar 

  18. Lipton RB, Apfel SC, Dutcher JP, Rosenberg R, Kaplan J, Berger A, Einzig Al, Wiernik P, Schaumburg HH: Taxol produces a predominantly sensory neuropathy. Neurology 1989 (39):368–373

    PubMed  CAS  Google Scholar 

  19. Schaumberg H, Kaplan J, Windebank A: Sensory neuropathy from pyridoxine abuse. N Engl J Med 1983 (309):445–448

    Article  Google Scholar 

  20. Denny-Brown D: Primary sensory neuropathy with muscular changes associated with carcinoma. J Neurol Neurosurg Psychiat 1948 (11):73–87

    Article  PubMed  CAS  Google Scholar 

  21. Horwich MS, Cho L, Porro RS et al: Subacute sensory neuropathy: a remote effect of carcinoma. Ann Neurol 1977 (2):7–19

    Article  PubMed  CAS  Google Scholar 

  22. Sterman AB, Schaumburg HH, Asbury AK: The acute sensory neuronopathy syndrome: A distinct clinical entity. Ann Neurol 1980 (7):354–358

    Article  PubMed  CAS  Google Scholar 

  23. Filley CM, Graff-Radford NR, Lacy JR, Heitner MA, Earnest MP: Neurotoxic manifestation of podophyllin toxicity. Neurology 1982 (32):308–311

    PubMed  CAS  Google Scholar 

  24. Falkson G, Van Dyk JJ, Van Eden EB, Van Der Merwe AM , Van Den Bergh JA, Falkson HC: A clinical trial of the oral form of 4’-demethylepipodophyllotoxin-B-D ethylidene glucoside (NSC 141540). Cancer 1975 (35):1141–1144

    Article  PubMed  CAS  Google Scholar 

  25. Left RS, Thompson JM, Daly MB, Johnson DB, Harden EA, Mercier RJ, Messerschmidt GL: Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma. Cancer 1988 (62):32–35

    Article  Google Scholar 

  26. EORTC Brain Tumor Group: Evaluation of CCNU, VM26, and procarbazine in sprasensorial bramigliomas. J Neurosurg 1981 (55):27–31

    Article  Google Scholar 

  27. Roelofs Rl, Hrushesky W, Rogin J, Rosenberg L: Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984 (34):934–938

    PubMed  CAS  Google Scholar 

  28. Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC: Cisplatin neuropathy, clinical, electrophysiologic, morphologic and toxicologic studies. Cancer 1984 (54):1269–1275

    Article  PubMed  CAS  Google Scholar 

  29. Ecles R, Talt DM, Peckham MJ: Lhermitte’s sign as a complication of cisplatin containing chemotherapy of testicular cancer. Cancer Treat Rep 1986 (70):905–907

    Google Scholar 

  30. Wright DE, Drouin P: Cisplatin-induced myasthenic syndrome. Clin Pharm 1982 (1):76–78

    PubMed  CAS  Google Scholar 

  31. Rosenfeld CS, Broder LE: Cisplatin-induced autonomic neuropathy. Cancer Treat Rep 1984 (68):659–660

    PubMed  CAS  Google Scholar 

  32. Kondo A, Ohnishi A, Nagara H, Tateishi J: Neurotoxicity in primary sensory neurons of adriamycin administered through retrograde axoplasmic transport in rats. Neuropathol Appl Neurobiol 1987(13):177–192

    Article  PubMed  CAS  Google Scholar 

  33. Castellanos AM, Glass JP, Yung WKA: Regional nerve injury after intra-arterial chemotherapy. Neurology 1987 (37):834–837

    PubMed  CAS  Google Scholar 

  34. Van Hoff DD, Schilsky R, Reichert et al: Toxic effects of cis-dichlorodiammineplatinum in man. Cancer Treat Rep 1979 (63):1527–1531

    Google Scholar 

  35. Melamed LB, Selim MA, Schulhman D: Cisplatin ototoxicity in gynecologic cancer patients. A preliminary report. Cancer 1985 (55):41–43

    CAS  Google Scholar 

  36. Schaefer SD, Post JD, Close LG, Wright CG: Ototoxicity of low-and moderate-dose cisplatin. Cancer 1985 (56):1934–1939

    Article  PubMed  CAS  Google Scholar 

  37. McHaney VA, Thibadoux G, Hayes FA, Green AA: Hearing loss in children receiving cisplatin chemotherapy. J Pediatrics 1983 (102):314–317

    Article  CAS  Google Scholar 

  38. Schaefer SD, Wright CG, Post JD, Frenkel EP: Cis platinum vestibular toxicity. Cancer 1981 (47):857–859

    Article  PubMed  CAS  Google Scholar 

  39. Brunner KW, Yound CW: A methylhydrazine derivative in Hodgkin’s disease and other malignant neoplasms: Therapeutic and toxic effects studied in 51 patients. Ann Intern Med 1965 (63):69–86

    PubMed  CAS  Google Scholar 

  40. Samuels ML, Leary WB, Alexanian R, Howe CD, Frei E: Clinical trials with N-isopropyl--(2 methylhydrazino)-p-tolnamide hydrochloride in malignant lymphoma and other disseminated neoplasms. Cancer 1967 (20):1187–1194

    Article  PubMed  CAS  Google Scholar 

  41. Spivack SD: Procarbazine, drugs five years later. Ann Inter Med 1974 (81):795–800

    CAS  Google Scholar 

  42. EORTC Brain Tumor Group: Misomidazole in radiotherapy of suprasensoriel indiquant brain gliomas in adult patients: a randomized double-blind study. Eur J Cancer Clin Oncol 1983 (19):39–42

    Article  Google Scholar 

  43. Stein CA, La Rocca RV, Thomas R, Mc Atee N, Myers CE: Suramin: An anticancer drug with a unique mechanism of action. J Clin Oncol 1989 (7):49–508

    Google Scholar 

  44. La Rocca R, Stein C, Myers C, Dalakas M, Mc Atee N: Suramin induced actue polyneuropathy. Proc ASC0 1989 (8):71

    Google Scholar 

  45. Legha SS, Slavik M, Carter SK: Hexamethylmelamine. An evaluation of its role in the therapy of cancer. Cancer 1976 (38):27–35

    Article  PubMed  CAS  Google Scholar 

  46. Neijt JP, Ten Bokkel Huinink WW, Van Der Burg ME, Van Oosterom AT et al: Randomized trial comparing two combination chemotherapy reginons in advanced ovarian carcinoma. Lancet 1984 (2):594–600

    Article  PubMed  CAS  Google Scholar 

  47. Levin JA, Wiernik PH: A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlymphocytic leukemia. Cancer 1976(38):36–41

    Article  Google Scholar 

  48. Lubitz JA, Freeman L, Okun R: Mitotane used in inoperable adrenal cortical carcinoma. Jama 1973 (223):1109–1112

    Article  PubMed  CAS  Google Scholar 

  49. McLennan R: In a letter to investigational drug branch. NCI, June 1976

    Google Scholar 

  50. Wilson WB, Perez GM, Kleinschmidt-De-Master BK: Sudden onset of blindness in patients treated with oral CCNU and low-dose cranial irradiation. Cancer 1987 (59):901–907

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de Neurologie, Hôpital Erasme, Route de Lennik 808, 1070, Brussels, Belgium

    Jerzy Hildebrand

Authors
  1. Jerzy Hildebrand
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Service de Neurologie, Hôpital Erasme Université Libre de Bruxelles, Route de Lennik, 808, 1070, Bruxelles, Belgium

    Jerzy Hildebrand

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Hildebrand, J. (1990). Peripheral Neuropathy. In: Hildebrand, J. (eds) Neurological Adverse Reactions to Anticancer Drugs. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76142-3_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-76142-3_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-76144-7

  • Online ISBN: 978-3-642-76142-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation